Table 4.
Prognostic factors for overall survival (OS) and progression-free survival (PFS) after stereotactic brachytherapy (SBT)
| Prognostic factor | No | % 5-/10-years OS | % 5-/10-years PFS | p-value OS/PFS |
|---|---|---|---|---|
| Sex | 0.45/0.50 | |||
| Female | 47 | 85/59 | 52/35 | |
| Male | 59 | 71/50 | 40/26 | |
| Age at first SBT | 0.68/0.55 | |||
| < 40 years | 50 | 79/59 | 46/25 | |
| > 40 years | 56 | 75/50 | 44/34 | |
| Tumor volume at SBT in ml | 0.15/0.44 | |||
| < 10 ml | 55 | 83/63 | 53/41 | |
| > 10 ml | 56 | 66/30 | 26/14 | |
| Histology | 0.75/0.06 | |||
| Astrocytoma | 90 | 76/54 | 47/31 | |
| Oligoastrocytoma/Oligodendroglioma | 16 | 79/57 | 28/– | |
| MGMT methylation | 0.73/0.80 | |||
| Yes | 42 | 87/53 | 37/– | |
| No | 9 | 75/– | 50/– | |
| LOH 1p/19q | 0.27/0.82 | |||
| Yes (= loss of either or both) | 20 | 94/74 | 52/– | |
| No | 27 | 76/40 | 37/20 |
OS, overall survival; PFS, progression-free survival; No, number; SBT, stereotactic brachytherapy; LOH, loss of heterozygosity; MGMT methylation, o-6methylguanine-DNA methyltransferase methylation